Automatic implantable cardioverter-defibrillator

Patient survival, battery longevity and shock delivery analysis

M. D. Gabry, R. Brodman, D. Johnston, R. Frame, Soo G. Kim, L. E. Waspe, John Devens Fisher, S. Furman

Research output: Contribution to journalArticle

113 Citations (Scopus)

Abstract

The automatic implantable cardioverter-defibrillator (AICD) has been shown to reduce the mortality rate of patients with malignant ventricular tachyarrhythmias. This report describes experience with implantation of 36 automatic implantable cardioverter-defibrillators (AID-B and AID-BR models) in 22 persons over a 44 month patient follow-up period (mean 19.6 months). There were five deaths: two patients died suddenly 22 and 29 months, respectively, after their second implant, one died of cogestive heart failure, one died of respiratory failure and one died of catheter sepsis. Although 11 (50%) of the 22 patients never received a countershock for a ventricular tachyarrhythmia and are still alive, the other 11 received one or more spontaneous countershocks. Nine patients (41%) experienced spurious shocks during the follow-up period. Assuming that the first shock for presumed ventricular tachyarrhythmia prevented death, the hypothetical cumulative survival of patients at 42 months would have been 34 ± 14.1% in the absence of an automatic implantable cardioverter defibrillator rather than the actual survival rate of 59 ± 16.8%. The cumulative device survival of the 36 AID-B units was 92 ± 5.62% at 15 months but diminished to 37 ± 14.4% by 20 months. No unit lasted longer than 22 months. There were 12 battery depletions. The number of shocks emitted did not influence unit longevity. The manufacturer's elective replacement indicator is of uncertain validity. Six units remained active 7 to 17 months after surpassing their replacement indicator. The automatic implantable cardioverter-defibrillator prolongs the life of many patients with otherwise intractable arrhythmias. Problems remain with this early generation device including the imprecision of its arrhythmia detection system resulting in false-positive discharges, the limited longevity of its battery, lack of programmability and an inadequate device follow-up system.

Original languageEnglish (US)
Pages (from-to)1349-1356
Number of pages8
JournalJournal of the American College of Cardiology
Volume9
Issue number6
StatePublished - 1987
Externally publishedYes

Fingerprint

Implantable Defibrillators
Shock
Survival
Tachycardia
Equipment and Supplies
Cardiac Arrhythmias
Respiratory Insufficiency
Sepsis
Catheters
Survival Rate
Heart Failure
Mortality

ASJC Scopus subject areas

  • Nursing(all)

Cite this

Automatic implantable cardioverter-defibrillator : Patient survival, battery longevity and shock delivery analysis. / Gabry, M. D.; Brodman, R.; Johnston, D.; Frame, R.; Kim, Soo G.; Waspe, L. E.; Fisher, John Devens; Furman, S.

In: Journal of the American College of Cardiology, Vol. 9, No. 6, 1987, p. 1349-1356.

Research output: Contribution to journalArticle

@article{e1d6c97a9f6f4a75944a8180558f75b1,
title = "Automatic implantable cardioverter-defibrillator: Patient survival, battery longevity and shock delivery analysis",
abstract = "The automatic implantable cardioverter-defibrillator (AICD) has been shown to reduce the mortality rate of patients with malignant ventricular tachyarrhythmias. This report describes experience with implantation of 36 automatic implantable cardioverter-defibrillators (AID-B and AID-BR models) in 22 persons over a 44 month patient follow-up period (mean 19.6 months). There were five deaths: two patients died suddenly 22 and 29 months, respectively, after their second implant, one died of cogestive heart failure, one died of respiratory failure and one died of catheter sepsis. Although 11 (50{\%}) of the 22 patients never received a countershock for a ventricular tachyarrhythmia and are still alive, the other 11 received one or more spontaneous countershocks. Nine patients (41{\%}) experienced spurious shocks during the follow-up period. Assuming that the first shock for presumed ventricular tachyarrhythmia prevented death, the hypothetical cumulative survival of patients at 42 months would have been 34 ± 14.1{\%} in the absence of an automatic implantable cardioverter defibrillator rather than the actual survival rate of 59 ± 16.8{\%}. The cumulative device survival of the 36 AID-B units was 92 ± 5.62{\%} at 15 months but diminished to 37 ± 14.4{\%} by 20 months. No unit lasted longer than 22 months. There were 12 battery depletions. The number of shocks emitted did not influence unit longevity. The manufacturer's elective replacement indicator is of uncertain validity. Six units remained active 7 to 17 months after surpassing their replacement indicator. The automatic implantable cardioverter-defibrillator prolongs the life of many patients with otherwise intractable arrhythmias. Problems remain with this early generation device including the imprecision of its arrhythmia detection system resulting in false-positive discharges, the limited longevity of its battery, lack of programmability and an inadequate device follow-up system.",
author = "Gabry, {M. D.} and R. Brodman and D. Johnston and R. Frame and Kim, {Soo G.} and Waspe, {L. E.} and Fisher, {John Devens} and S. Furman",
year = "1987",
language = "English (US)",
volume = "9",
pages = "1349--1356",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "6",

}

TY - JOUR

T1 - Automatic implantable cardioverter-defibrillator

T2 - Patient survival, battery longevity and shock delivery analysis

AU - Gabry, M. D.

AU - Brodman, R.

AU - Johnston, D.

AU - Frame, R.

AU - Kim, Soo G.

AU - Waspe, L. E.

AU - Fisher, John Devens

AU - Furman, S.

PY - 1987

Y1 - 1987

N2 - The automatic implantable cardioverter-defibrillator (AICD) has been shown to reduce the mortality rate of patients with malignant ventricular tachyarrhythmias. This report describes experience with implantation of 36 automatic implantable cardioverter-defibrillators (AID-B and AID-BR models) in 22 persons over a 44 month patient follow-up period (mean 19.6 months). There were five deaths: two patients died suddenly 22 and 29 months, respectively, after their second implant, one died of cogestive heart failure, one died of respiratory failure and one died of catheter sepsis. Although 11 (50%) of the 22 patients never received a countershock for a ventricular tachyarrhythmia and are still alive, the other 11 received one or more spontaneous countershocks. Nine patients (41%) experienced spurious shocks during the follow-up period. Assuming that the first shock for presumed ventricular tachyarrhythmia prevented death, the hypothetical cumulative survival of patients at 42 months would have been 34 ± 14.1% in the absence of an automatic implantable cardioverter defibrillator rather than the actual survival rate of 59 ± 16.8%. The cumulative device survival of the 36 AID-B units was 92 ± 5.62% at 15 months but diminished to 37 ± 14.4% by 20 months. No unit lasted longer than 22 months. There were 12 battery depletions. The number of shocks emitted did not influence unit longevity. The manufacturer's elective replacement indicator is of uncertain validity. Six units remained active 7 to 17 months after surpassing their replacement indicator. The automatic implantable cardioverter-defibrillator prolongs the life of many patients with otherwise intractable arrhythmias. Problems remain with this early generation device including the imprecision of its arrhythmia detection system resulting in false-positive discharges, the limited longevity of its battery, lack of programmability and an inadequate device follow-up system.

AB - The automatic implantable cardioverter-defibrillator (AICD) has been shown to reduce the mortality rate of patients with malignant ventricular tachyarrhythmias. This report describes experience with implantation of 36 automatic implantable cardioverter-defibrillators (AID-B and AID-BR models) in 22 persons over a 44 month patient follow-up period (mean 19.6 months). There were five deaths: two patients died suddenly 22 and 29 months, respectively, after their second implant, one died of cogestive heart failure, one died of respiratory failure and one died of catheter sepsis. Although 11 (50%) of the 22 patients never received a countershock for a ventricular tachyarrhythmia and are still alive, the other 11 received one or more spontaneous countershocks. Nine patients (41%) experienced spurious shocks during the follow-up period. Assuming that the first shock for presumed ventricular tachyarrhythmia prevented death, the hypothetical cumulative survival of patients at 42 months would have been 34 ± 14.1% in the absence of an automatic implantable cardioverter defibrillator rather than the actual survival rate of 59 ± 16.8%. The cumulative device survival of the 36 AID-B units was 92 ± 5.62% at 15 months but diminished to 37 ± 14.4% by 20 months. No unit lasted longer than 22 months. There were 12 battery depletions. The number of shocks emitted did not influence unit longevity. The manufacturer's elective replacement indicator is of uncertain validity. Six units remained active 7 to 17 months after surpassing their replacement indicator. The automatic implantable cardioverter-defibrillator prolongs the life of many patients with otherwise intractable arrhythmias. Problems remain with this early generation device including the imprecision of its arrhythmia detection system resulting in false-positive discharges, the limited longevity of its battery, lack of programmability and an inadequate device follow-up system.

UR - http://www.scopus.com/inward/record.url?scp=0023277488&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023277488&partnerID=8YFLogxK

M3 - Article

VL - 9

SP - 1349

EP - 1356

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 6

ER -